Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106137402 | 10613740 | 2 | F | 20160914 | 20141128 | 20160921 | PER | US-ELI_LILLY_AND_COMPANY-US201411006940 | ELI LILLY AND CO | 74.00 | YR | F | Y | 78.90000 | KG | 20160921 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106137402 | 10613740 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Oral | 40 MG, QD | 21368 | 40 | MG | TABLET | QD | ||||||
| 106137402 | 10613740 | 2 | SS | LASIX | FUROSEMIDE | 1 | Oral | 80 MG, QD | 0 | 80 | MG | QD | |||||||
| 106137402 | 10613740 | 3 | C | PRAVASTATIN. | PRAVASTATIN | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 4 | C | VITAMIN B COMPLEX | CYANOCOBALAMINDEXPANTHENOLNIACINAMIDEPYRIDOXINE HYDROCHLORIDERIBOFLAVIN 5'-PHOSPHATE SODIUMTHIAMINE HYDROCHLORIDEVITAMIN B COMPLEX | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 5 | C | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 6 | C | CARVEDILOL. | CARVEDILOL | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 7 | C | TOCOFEROL | TOCOPHEROL | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 8 | C | CALCIUM WITH VITAMIN D /00944201/ | CALCIUM CARBONATECHOLECALCIFEROL | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 9 | C | FISH OIL | FISH OIL | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 10 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 11 | C | BENICAR | OLMESARTAN MEDOXOMIL | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 12 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 13 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | UNK | 0 | |||||||||||
| 106137402 | 10613740 | 14 | C | NAPROXEN. | NAPROXEN | 1 | Unknown | UNK, UNKNOWN | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106137402 | 10613740 | 1 | Pulmonary hypertension |
| 106137402 | 10613740 | 2 | Pulmonary oedema |
| 106137402 | 10613740 | 3 | Blood cholesterol increased |
| 106137402 | 10613740 | 5 | Depression |
| 106137402 | 10613740 | 10 | Hypertension |
| 106137402 | 10613740 | 11 | Hypertension |
| 106137402 | 10613740 | 12 | Prophylaxis |
| 106137402 | 10613740 | 13 | Blood cholesterol increased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106137402 | 10613740 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106137402 | 10613740 | Hypotension |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106137402 | 10613740 | 1 | 20110921 | 0 | ||
| 106137402 | 10613740 | 2 | 20110810 | 0 | ||
| 106137402 | 10613740 | 3 | 2008 | 0 | ||
| 106137402 | 10613740 | 4 | 2009 | 0 | ||
| 106137402 | 10613740 | 5 | 2006 | 0 | ||
| 106137402 | 10613740 | 6 | 2006 | 0 | ||
| 106137402 | 10613740 | 7 | 2008 | 0 | ||
| 106137402 | 10613740 | 8 | 2008 | 0 | ||
| 106137402 | 10613740 | 9 | 2008 | 0 | ||
| 106137402 | 10613740 | 10 | 20110602 | 0 | ||
| 106137402 | 10613740 | 11 | 20110602 | 0 | ||
| 106137402 | 10613740 | 12 | 20110610 | 0 | ||
| 106137402 | 10613740 | 13 | 2008 | 0 | ||
| 106137402 | 10613740 | 14 | 20110610 | 20120507 | 0 |